As more SLE patients are treated with anti-CD19 CAR T cell therapies, the contribution of short-lived, long-lived, CD19−, and CD19+ antibody secreting populations to autoantibody production may be further elucidated. The gene discussed is CD19; the disease is systemic lupus erythematosus.